Pacira BioSciences, Inc. PCRX
Pacira BioSciences, Inc., a Delaware corporation, is the holding company for our California operating subsidiary named Pacira Pharmaceuticals, Inc. In March 2007, we acquired Pacira Pharmaceuticals, Inc. from SkyePharma Holdings, Inc. (now Vectura Group Limited, a subsidiary of Molex Asia Holdings, Ltd.), or Skyepharma (the "Skyepharma Acquisition"). In April 2019, we acquired MyoScience, Inc., a privately held medical technology company (the "MyoScience Acquisition"), in November 2021, we acquired Flexion Therapeutics, Inc., or Flexion, a publicly traded biopharmaceutical company (the "Flexion Acquisition") and in February 2025, we acquired GQ Bio Therapeutics GmbH, or GQ Bio, a privately-held biopharmaceutical company (the "GQ Bio Acquisition"). Unless the context requires otherwise, references to "Pacira," "we," the "Company," the "Registrant," "us" and "our" in this Annual Report refers to Pacira BioSciences, Inc., a Delaware corporation, and its subsidiaries.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $726.4M | $701.0M | $675.0M | $666.8M | $541.5M | $429.6M | $418.9M | $332.4M | $284.3M | $270.1M |
| Cost of revenue | $149.7M | $170.4M | $184.7M | $199.3M | $140.3M | $117.3M | $106.7M | $86.8M | $87.9M | $110.1M |
| Gross profit | $576.7M | $530.5M | $490.3M | $467.5M | $401.3M | $312.3M | $312.2M | $245.6M | $196.4M | $160.0M |
| R&D | $117.3M | $81.6M | $76.3M | $84.8M | $55.5M | $59.4M | $72.1M | $55.7M | $57.3M | $45.7M |
| SG&A | $368.8M | $294.1M | $269.4M | $254.5M | $199.3M | $193.5M | $200.8M | $177.3M | $161.5M | $152.6M |
| Total operating expenses | $707.2M | $774.3M | $587.3M | $606.8M | $451.6M | $383.3M | $410.5M | $321.4M | $311.6M | $308.4M |
| Operating income | $19.2M | -$73.4M | $87.7M | $60.0M | $89.9M | $46.4M | $10.5M | $15.9M | -$24.9M | -$32.0M |
| Interest expense | $17.4M | $16.6M | $20.3M | $40.0M | $31.8M | $25.7M | $23.6M | $21.9M | $18.0M | $7.1M |
| Pre-tax income | $16.9M | -$63.1M | $61.7M | $13.3M | $56.4M | $20.1M | -$10.7M | -$425.0K | -$42.5M | -$37.8M |
| Income tax | $9.8M | $36.5M | $19.7M | $2.6M | $14.4M | $125.4M | $268.0K | $46.0K | $140.0K | $105.0K |
| Net income | $7.0M | -$99.6M | $42.0M | $15.9M | $42.0M | $145.5M | -$11.0M | -$471.0K | -$42.6M | -$37.9M |
| EPS, basic | 0.16 | -2.15 | 0.91 | 0.35 | 0.95 | 3.41 | -0.27 | -0.01 | -1.07 | -1.02 |
| EPS, diluted | 0.16 | -2.15 | 0.89 | 0.34 | 0.92 | 3.33 | -0.27 | -0.01 | -1.07 | -1.02 |
| Shares, diluted (wtd. avg.) | $45.0M | $46.2M | $52.0M | $46.5M | $45.6M | $43.7M | $41.5M | $40.9M | $39.8M | $37.2M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $158.5M | $276.8M | $153.3M | $104.1M | $585.6M | $100.0M | $78.2M | $132.5M | $54.1M | $35.9M |
| Short-term investments | $79.9M | $207.8M | $125.3M | $184.5M | $70.8M | $421.7M | $213.7M | $250.9M | $257.2M | $136.7M |
| Receivables | $124.1M | $113.3M | $105.6M | $98.4M | $96.3M | $53.0M | $47.5M | $38.0M | $31.7M | $29.9M |
| Inventory | $152.9M | $125.3M | $104.4M | $96.1M | $98.5M | $64.7M | $58.3M | $48.6M | $41.4M | $31.3M |
| Total current assets | $548.0M | $745.1M | $510.0M | $498.3M | $866.0M | $651.6M | $408.6M | $478.0M | $391.1M | $243.1M |
| Property, plant and equipment | $140.7M | $167.2M | $173.9M | $183.5M | $188.4M | $136.7M | $104.7M | $108.7M | $107.0M | $101.0M |
| Goodwill | $20.2M | $0 | $163.2M | $163.2M | $145.2M | $99.5M | $99.5M | $62.0M | $55.2M | $46.7M |
| Other intangibles | $368.1M | $426.0M | $483.3M | $540.5M | $624.0M | $96.5M | $104.4M | $0 | — | $0 |
| Total assets | $1.26B | $1.55B | $1.57B | $1.68B | $2.08B | $1.27B | $831.1M | $689.4M | $628.4M | $391.5M |
| Accounts payable | $15.2M | $19.1M | $15.7M | $15.2M | $10.5M | $10.4M | $12.8M | $14.4M | $14.7M | $7.5M |
| Short-term debt | $0 | $201.8M | — | — | — | — | — | — | — | $118.5M |
| Total current liabilities | $120.6M | $309.9M | $97.4M | $147.8M | $521.1M | $253.3M | $107.7M | $60.7M | $56.2M | $44.8M |
| Long-term debt | $372.2M | $383.5M | $522.4M | $689.5M | — | — | — | — | — | $108.7M |
| Total liabilities | $571.8M | $775.2M | $704.3M | $906.2M | $1.34B | $654.8M | $476.1M | $368.1M | $348.9M | $172.5M |
| Retained earnings | -$199.3M | -$206.4M | -$106.8M | -$148.8M | -$211.9M | -$253.9M | -$399.4M | -$388.2M | -$389.1M | -$346.2M |
| Total equity | $693.1M | $778.3M | $870.1M | $775.0M | $730.4M | $619.7M | $354.9M | $321.2M | $279.5M | $219.0M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $152.0M | $189.4M | $154.6M | $145.3M | $125.7M | $77.0M | $70.5M | $48.9M | $17.8M | $33.5M |
| Depreciation and amortisation | $91.0M | $78.8M | $75.6M | $91.5M | $28.5M | $19.9M | $19.6M | $13.2M | $13.8M | $12.9M |
| Stock-based compensation | $57.5M | $51.2M | $47.9M | $48.1M | $42.2M | $39.9M | $33.6M | $31.7M | $31.6M | $31.2M |
| Capital expenditure | $15.3M | $10.6M | $15.2M | $30.1M | $45.9M | $37.8M | $10.2M | $14.5M | $19.3M | $24.7M |
| Investing cash flow | $99.5M | -$83.3M | $77.5M | -$225.2M | -$20.8M | -$277.6M | -$128.5M | $20.6M | -$223.8M | -$61.8M |
| Financing cash flow | -$369.6M | $17.4M | -$183.0M | -$401.5M | $380.7M | $222.3M | $3.7M | $9.0M | $224.2M | $7.3M |
| Buybacks | $148.3M | $25.0M | $0 | $0 | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-050353.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |